# Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME)

> **NCT01135914** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 241 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** ranibizumab
- **PROCEDURE:** Laser

## Key facts

- **NCT ID:** NCT01135914
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 241 (ACTUAL)
- **Last updated:** 2014-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01135914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01135914, "Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01135914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*